A second line of defense — the immune system’s T cells — may offer protection from COVID-19 even when vaccine-induced antibodies no longer can, according to new research out of the University of Wisconsin School of Veterinary Medicine.
By exploring the ways mice responded, researchers hope to gain an understanding of the sorts of human health issues that may bring on a case of this life-threatening form of cancer.
Called manifold learning, the approach may help researchers better understand and even predict brain disorders by looking at specific neuronal properties.
Ketamine has been shown to relieve depression-like symptoms in animal studies. With human volunteers, researchers Sounak Mohanta and Yuri Saalmann concluded that the drug blocks “negative predictions” that are prominent in depressed patients.
The discovery could help people with muscle-wasting disorders and even astronauts on extended space voyages by putting space travelers into a hibernation-like state.
Public health officials expect antiviral pills to become an increasingly common treatment for COVID-19 that will reduce the severity of the disease in at-risk patients and decrease the burden of the pandemic.
If the world already had a pan-coronavirus vaccine in March 2020, it could have served as a mitigation tool until vaccines specific to SARS-CoV-2 could be developed.
A new study could lead to earlier diagnosis of epilepsy and possibly new ways to treat epilepsy and other disorders that share symptoms, like Alzheimer’s disease, traumatic brain injury and autism spectrum disorder.
The rare neurological disorder has no cure and is typically fatal, but a study led by UW–Madison researchers is a significant step in efforts to help people with the disease.
UW–Madison and University of Pittsburgh scientists report the method works even when the radiation is given in doses too low to destroy the cancer outright.